Showing 1481-1490 of 1692 results for "".
Exploring the Use of Cannabidiol in Epilepsy Management
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/exploring-the-use-of-cannabidiol-in-epilepsy-management/30447/Existing literature is compelling enough to warrant further studies to determine the safety, efficacy, and benefits of cannabinoids.MR CLEAN: A Close-Up Look
https://practicalneurology.com/diseases-diagnoses/stroke/mr-clean-a-close-up-look/30591/A co-principal investigator details the landmark stroke study and discusses how to avoid a turf war with competing specialties.Dizziness and Vertigo
https://practicalneurology.com/diseases-diagnoses/headache-pain/dizziness-and-vertigo/30119/Part 1: Untangling the complexity of dizziness and vertigo requires a careful history.- Purple Day Is Coming on March 26, 2021 With Education and Advocacy to Destigmatize Epilepsyhttps://practicalneurology.com/news/purple-day-is-coming-on-march-26-2021-with-education-and-advocacy-to-destigmatize-epilepsy/2469531/Purple Day is coming soon on March 26th, 2021 epilepsy specialists, people living with epilepsy, and adv
- FDA Approves Neonatal Fc Receptor Blocker Treatment for Individuals with Generalized Myasthenia Gravishttps://practicalneurology.com/news/fda-approves-neonatal-fc-receptor-blocker-treatment-for-individuals-with-generalized-myasthenia-gravis/2474395/The Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab; Johnson & Johnson, New Brunswick, NJ) for the treatment of individuals aged >12 years with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK)
- Expanded Access to Free Genetic Testing for Children with Epilepsyhttps://practicalneurology.com/news/expanded-access-to-free-genetic-testing-for-children-with-epilepsy/2468824/Eligibility for a program that provides free genetic testing for epilepsy in young children has been expanded. The Behind the Seizure program, which had been available for patients age 2 to 4 years with a history of 1 or more unprovoked seizures, is now offered for children from birth to age 5 ye
- Free Resource for People Living With Migraine—Migraine Patient Guidelineshttps://practicalneurology.com/news/free-resource-for-people-living-with-migrainemigraine-patient-guidelines/2468776/A new publication for people living with migraine, Migraine Patient Guidelines from The Global Healthy Living Foundation, is available for free download to assist people living with migraine.
- AES Announces Free Training in Epilepsy Diagnosis Using EEGhttps://practicalneurology.com/news/aes-announces-free-training-in-epilepsy-diagnosis-using-eeg/2470562/The American Epilepsy Society (AES) has launched the AES EEG Essentials curriculum---a free series of educational curricula focused on improving the diagnostic skills of health care providers. AES EEG Essentials is designed with the aim of reducing and closing the diagnostic gap in epilepsy, whic
- More Sites Offer Free Parkinson Disease Genetic Testing and Counselinghttps://practicalneurology.com/news/more-sites-offer-free-parkinson-disease-genetic-testing-and-counseling/2469122/The Parkinson's Foundation has added 5 new sites for PD GENEration: Mapping the Future of Parkinson's Disease, a first-of-its-kind national initiative that offers free genetic testing and counseling for clinically relevant Parkinson disease (PD)-related genes. The new sites include Massac
- Treatment of Focal Epilepsy with Cenobamate Associated with Lower Inpatient Days and ER Visits Compared with 7 Leading Anti-Seizure Medicationshttps://practicalneurology.com/news/treatment-of-focal-epilepsy-with-cenobamate-associated-with-lower-inpatient-days-and-er-visits-compared-with-7-leading-anti-seizure-medications/2470448/The addition of cenobamate to the treatment regimens of people with focal epilepsy was associated with lower rates of inpatient days and emergency room (ER) visits compared with the addition of 7 other leading anti-seizure medications (ASMs). This finding, which was presented at the American Acad